CASI Pharmaceuticals, Inc. (CASIF): Cash & Equivalents
$5.63M
As of 2025-12-31
-50.7%
3-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $5.63M | -58.2% | 2026-05-15, Balance as of period end |
| 2024-12-31 | $13.47M | -21.2% | 2026-05-15, Balance as of period end |
| 2023-12-31 | $17.08M | -63.7% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $47.11M | +21.7% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $38.70M | n/a | 2023-04-26, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $5.63M | -58.2% |
| Scynexis Inc (SCYX) | 2025-12-31 | $21.26M | +32.4% |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | $578.0K | -22.0% |
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $11.03M | -43.4% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $490.00M | -36.5% |
| Alumis Inc. (ALMS) | 2025-12-31 | $89.67M | -47.1% |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $90.39M | -10.7% |
| Celularity Inc (CELU) | 2025-12-31 | $6.17M | +736.7% |
| uniQure N.V. (QURE) | 2025-12-31 | $80.24M | -49.5% |
Compare CASIF, SCYX, EVFM, SLGL side by side · Screen every company in Pharmaceutical Preparations ↗